Cardiovascular disease including coronary artery disease and myocardial infarction is one of the leading causes of death in Europe, and is influenced by both environmental and genetic factors.
causes around 735,000 heart attacks in the US every year (Mozaffarian et al. 2015) . A large number of scientific advances have been made to prevent, diagnose and treat AMI but unfortunately it is still a leading cause of worldwide morbidity and mortality.
The current diagnosis of AMI is based on potential clinical symptoms including chest pain and impaired breathing and changes in the pattern of ECG and a significant rise and subsequent fall in the circulating levels of cardiac troponins (cTns) (Thygesen et al. 2007 ). Despite the advances in the cardiovascular field there are several limitations in the current diagnostic system. The advancements in hs-cTn assays have made it possible to detect 10 fold lower circulating Tn concentrations but it has also elevated the number of cardiovascular patients by counting clinically non-diseased people showing changes in cTns due to other conditions (Eggers et al. 2009 ). Another diagnostic measure is the detection of cardiac miRNAs, which are introduced as sensitive biomarkers (Wang et The majority of cardiac biomarkers are developed using the knowledge of pathological and physiological processes in established pathways. In contrast microarray platforms measure the expression of a large number of genes simultaneously, enabling gene expression profiling across many pathways in parallel. This approach has the potential to represent a comprehensive range of pathophysiological processes of cardiovascular diseases economically and efficiently (Pedrotty et al. 2012 ). Gene expression profiling extends beyond known biomarkers to reveal biomarkers which are not already known and not previously associated to heart disease.
Gene expression analysis can help to understand and discover novel and sensitive biomarkers of cardiovascular disease. A gene expression analysis yielded 482 genes with an association to the composition of coronary atherosclerotic plaques and most of them were not previously linked to atherosclerosis (Randi et al. 2013) . A wide-scale gene expression profiling identified fifty six divergent genes for atherosclerotic and non-atherosclerotic human coronary arteries, wherein 49 were never associated with CAD before (Archacki et al. 2003 ). Elashoff and co-authors identified a set of classifying genes which with the information of age and sex were strongly correlated to obstructive CAD in non-diabetic patients (Elashoff et al. 2011 ). The divergent gene expressions were identified which discriminated ischemic and non-ischemic cardiomyopathies conditions among the end-stage patients (Kittleson et al. 2004; Kittleson et al. 2005) . Microarray analysis and gene expression profiling were used to discover genes related to heart failure using the expression profiles of 12 patients with heart failure (Min et al. 2010 ), another study of normal controls and AMI patients discovered genetic markers and dysregulated pathways associated with disease recurrence in first time AMI patients (Suresh et al. 2014 ).
Despite a range of studies exploring differential expression in cardiovascular outcomes no attempt to use this information to classify patients according to outcome (eg unstable angina and AMI) has been reported yet. If successful this approach offers the potential to provide a diagnostic tool to sub-classify patients. In this work, we identified the discriminatory features to differentiate among normal controls, patients with AMI, stable coronary artery disease (CAD) and unstable angina using gene expression in blood cells. This paper also discusses the success and classification accuracy of different proposed algorithms implemented to discover the potential divergent gene expression features of heart diseases and their optimisation to explore the subset of most discriminatory features. Classifier Development-The expression measures of NelsonA were used to extract the initial differential features and to build the classifier. We used NelsonA to optimise the initial set of features in three different optimisation techniques and generated several subsets. We then used Nelson flow chart explaining the discovery and validation process of these two classifiers is given in Figure 1 and a detailed description of the methodology is written below.
Methods-Incorporated Datasets
Features Selection (Discovery Phase)-Initial divergent features were discovered using two different approaches which are described below.
P-Values based Selection (Discovery Method 1)-A linear model (lmFit) was fitted to training
samples and then an empirical Bayes method was used to compute the p-values corresponding to the t-statistics of differential expression (Smyth 2005) . The probe sets (PS) were ranked according to their most significant p-values, which were adjusted by using Benjamini and Hochberg (BH) method. The BH method controls the expected false discovery rate (FDR) below a specified threshold and is considered an appropriate choice for microarray experiments (Benjamini and Hochberg 1995) . The top 600 genes were selected as the initial classifier. Features Optimisation-We developed three different optimisation algorithms to identify the most discriminatory features in two basic lists identified in Discovery Method 1 and Discovery Method 2.
LOOCV t-tests (Discovery
All methods processed both lists individually. NelsonA dataset was used to optimise the lists.
Optimisation on Success Rate [Optimisation 1]-Initiated with the top two PS and tested using
LOOCV on the NelsonA samples. Then on the next iteration, the next PS was included and tested using LOOCV again. This was repeated until all PS were processed. After processing of each new PS, we recorded the classifiers success rate (SR; classification accuracy). PS which impaired the performance were eliminated from the list and were given no opportunity for any further LOOCV.
The optimisation of features discovered in Method 1 reduced 600 PS to 155 and the features of Random sampling was performed to ensure that the achieved performance was not due to the sampling effects.
A performance comparison of several optimised lists is given in Table 1 , these measures were used to select the final classifiers. The enrichment analysis of the genes identified in Subset 1 and Subset 2 was done using a web tool BioMart and the enrichments network is shown in Figure 2 . We compared the classifying PS lists with 157 probe sets identified in Nelson work (Suresh et al. 2014) and no overlap was seen.
Independent Validation
The Subset 1 was used to classify the independent data set Rothman (n=52) using NelsonA dataset as The SR, sensitivity, FPR and precision were 65%, 0.82, 0.67 and 0.7 respectively.
For the classification of Beata dataset (n=98), we mapped our classifying probe sets to HuGene-1_0-st platform using BioMart (http://www.biomart.org/). We successfully mapped all probe sets of the Subset 1 but three probe sets of the Subset 2 were missing. The gene expressions were normalised using RMA method. We called CAD patients our controls and STEMI the cases, performed 15 times random sampling and classified all samples in a LOOCV manner. The random sampling was included to keep the groups balanced for the KNN. The average classification accuracy for the Subset 1 and the Subset 2 was 88% and 96% respectively.
For the classification of Gregg data set, all classifying probe sets of the Subset 1 were mapped to Illumina platform using BioMart. The average bead signals were transformed to log2 scale and were normalised using quantile normalisation (Yang and Thorne 2003) . 14,343 probes among 47,211 were constantly detected above the background. The subjects were recruited in two phases and 14,111 probe sets were common in both phases. Unfortunately, one of our mapped probe set was among these 232 missing probes. We considered individuals with FINE phenotype as our controls and AMI as the cases. The LOOCV was performed using the Subset 1 and classified 154 patients after performing fifteen time random sampling. The recorded average SR was 65%.
The receiver operating characteristics (ROC) curve was plotted to measure the quality of both classifiers (Figure 3 ). The ROC analysis categorised MI patients as positive case and non-MI as negative cases.
Discussion-We used NelsonA data set to discover the divergent features between normal controls and AMI patients using two different methods; Discovery Method1 and Discovery Method 2. We identified two separate classifying lists where 461 probe sets were overlapping but were at different positions. We then applied three different optimisation techniques on both lists using NelsonA dataset and generated six different optimised lists. Then, we used Nelson and Rothman datasets to select our final classifiers and the selection criteria was the highest classification accuracy. The selected classifiers were independently validated on Nelson, Rothman, Beata and Gregg datasets following two procedures LOOCV and blind validation.
The ROC analysis was carried out to prove the diagnostic potential of our binary classifiers. In Figure 3 ). The FPR is again very high because the negative cases of the test dataset (normal controls; NelsonB) were not truly negative. Patients with unstable angina and AMI share many characteristics and our classifier showed a potential to differentiate patients of cardiac ischemia with myocardial necrosis from patients of cardiac ischemia but without myocardial necrosis.
Beata data has a population of STEMI and CAD patients and was classified in a LOOCV manner, where both the training and test samples were from the same dataset. For its classification, Subset 2, which was selected using the information of two diseases (AMI and unstable angina) showed higher measures of both sensitivity and specificity as compared to Subset 1 (Subset1 on Beata, Subset2 on Beata; Figure 3 ). The Gregg dataset has FINE and AMI patients therefore we considered only Subset 1 for its classification because this list was discovered using the information of AMI and normal individuals (Subset1 on Gregg; Figure 3 ). The ROC analysis indicates good sensitivity and specificity, indicating its reliability and robustness despite the fact that not all classifying probes sets of Subset 1 could be used and the samples were analysed using a completely different platform. Our results support the utilization of the discovered genes and proposed methods in the diagnosis of cardiovascular diseases using blood gene expression, and suggest potential clinical applications of gene expression data as biomarkers in cardiovascular disease.
Comparison with Random Forest-We compared our classifier's performance with a well-known machine learning algorithm Random Forest (Breiman 2001 ). The Random Forest classifier was first trained using all genes of the Affymetrix Human Genome U133 plus 2.0 chip and the training data set was NelsonA and then on top 600 significant p-valued genes. The cross validation of random forest classifiers on NelsonB showed 59% SR which is substantially weaker than our classifier's performances (95% SR of Subset 1 on NelsonB using NelsonA as a training set). 
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